08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF); adhesion G protein-coupled receptor E1 (ADGRE1)

Hepatic disease INDICATION: Hepatic Mouse studies suggest a bispecific macrophage-targeting antibody against TNF and ADGRE1 could help prevent liver damage. In a human TNF-expressing mouse model of chemical-induced fatal liver damage, pretreatment with a bispecific antibody containing...